In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Idexx Laboratories, Inc (NASDAQ: IDXX) closed at $701.83 up 0.40% from its previous closing price of $699.06. In other words, the price has increased by $0.40 from its previous closing price. On the day, 0.53 million shares were traded. IDXX stock price reached its highest trading level at $707.455 during the session, while it also had its lowest trading level at $693.75.
Ratios:
For a deeper understanding of Idexx Laboratories, Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 269.21 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 58.16. For the most recent quarter (mrq), Quick Ratio is recorded 0.81 and its Current Ratio is at 1.12. In the meantime, Its Debt-to-Equity ratio is 0.71 whereas as Long-Term Debt/Eq ratio is at 0.31.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $850.
On October 31, 2025, Stifel Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $700.
On October 01, 2025, UBS started tracking the stock assigning a Neutral rating and target price of $720.UBS initiated its Neutral rating on October 01, 2025, with a $720 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 07 ’25 when Hunt Nimrata sold 9,425 shares for $703.34 per share. The transaction valued at 6,629,014 led to the insider holds 21,149 shares of the business.
NIMRATA K HUNT bought 9,425 shares of IDXX for $6,629,060 on Nov 07 ’25. On Aug 22 ’25, another insider, SZOSTAK M ANNE, who serves as the Director of the company, sold 2,187 shares for $647.33 each. As a result, the insider received 1,415,700 and left with 262 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IDXX now has a Market Capitalization of 56149696512 and an Enterprise Value of 56946855936. As of this moment, Idexx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 55.64, and their Forward P/E ratio for the next fiscal year is 48.58. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.14. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.45 while its Price-to-Book (P/B) ratio in mrq is 35.96. Its current Enterprise Value per Revenue stands at 13.665 whereas that against EBITDA is 39.621.
Stock Price History:
The Beta on a monthly basis for IDXX is 1.67, which has changed by 0.59902096 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, IDXX has reached a high of $769.98, while it has fallen to a 52-week low of $356.14. The 50-Day Moving Average of the stock is 3.58%, while the 200-Day Moving Average is calculated to be 24.65%.
Shares Statistics:
For the past three months, IDXX has traded an average of 517.26K shares per day and 510090 over the past ten days. A total of 80.00M shares are outstanding, with a floating share count of 78.97M. Insiders hold about 1.10% of the company’s shares, while institutions hold 92.83% stake in the company. Shares short for IDXX as of 1764288000 were 2222573 with a Short Ratio of 4.30, compared to 1761868800 on 1715671. Therefore, it implies a Short% of Shares Outstanding of 2222573 and a Short% of Float of 3.65.
Earnings Estimates
The market rating for Idexx Laboratories, Inc (IDXX) is a result of the insights provided by 10.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $3.41, with high estimates of $3.54 and low estimates of $3.28.
Analysts are recommending an EPS of between $13.0 and $12.63 for the fiscal current year, implying an average EPS of $12.9. EPS for the following year is $14.42, with 12.0 analysts recommending between $14.97 and $14.11.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $1.07B this quarter.It ranges from a high estimate of $1.08B to a low estimate of $1.07B. As of. The current estimate, Idexx Laboratories, Inc’s year-ago sales were $954.29MFor the next quarter, 10 analysts are estimating revenue of $1.1B. There is a high estimate of $1.13B for the next quarter, whereas the lowest estimate is $1.08B.
A total of 13 analysts have provided revenue estimates for IDXX’s current fiscal year. The highest revenue estimate was $4.29B, while the lowest revenue estimate was $4.28B, resulting in an average revenue estimate of $4.29B. In the same quarter a year ago, actual revenue was $3.9BBased on 13 analysts’ estimates, the company’s revenue will be $4.66B in the next fiscal year. The high estimate is $4.72B and the low estimate is $4.62B.
